Azur Pharma Limited (“Azur Pharma”) today announced that it has acquired the U.S. rights to Gastrocrom® (cromolyn sodium, usp Oral Concentrate) from UCB Pharma, Inc (“UCB”).  Gastrocrom® is indicated in the management of patients suffering from mastocytosis, a rare disorder characterized by an abnormal accumulation of mast cells in various organ systems.  Annual sales of Gastrocrom® amount to approximately US$5 million.

“I am pleased to announce our first product acquisition, Gastrocrom®, a mature and stable prescription product indicated for a rare and often chronic disorder.  This acquisition is an important first step as we seek to execute on our mission of creating a U.S. pharmaceutical business focused on developing and marketing products in specialist therapeutic areas.” commented Mr. Seamus Mulligan, Azur Pharma’s Chairman and Chief Executive Officer.

www.edgemontcapital.com

CONTACT:


At Edgemont Capital Partners

David K. Blume Managing Director
Phone: 212-867-8935 Fax: 212-214-0911 Email: david@edgemontcapital.com

Jeff B. Swearingen Principal
Phone: 212-867-8935 Fax: 212-937-3816 Email: jeff@edgemontcapital.com